Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Cigna

MINNEAPOLIS, Feb. 24, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Cigna has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent(R) PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. The new policy applies to approximately 14 million lives covered by Cigna and was effective February 15, 2015.

"This positive coverage decision by Cigna brings the total U.S. access to Urgent PC therapy to approximately 123 million lives covered by private payers in addition to over 50 million Medicare beneficiaries," said Rob Kill, President and CEO of Uroplasty. "This decision further illustrates the medical necessity of PTNS and its value to patients and physicians trying to manage the symptoms of OAB. Urgent PC is a recommended third line treatment within the OAB treatment guidelines for patients who have not responded or cannot tolerate behavioral intervention and pharmacologic agents. The treatment guidelines are issued jointly by the American Urology Association (AUA) and Society for Urodynamics and Female Urology (SUFU).

About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 42 million US adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC Neuromodulation System is the only commercially available FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.  

About Uroplasty
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Uroplasty's focus is the continued commercialization of its Urgent® PC Neuromodulation System, which Uroplasty believes is the only commercially available, FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Uroplasty and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information: Uroplasty, Inc. Brett Reynolds, SVP and CFO 952-426-6152   EVC Group Doug Sherk/Brian Moore (Investors) 415-652-9100/310-579-6199 Janine McCargo (Media) 646-688-0425

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uroplasty-announces-positive-coverage-decision-for-percutaneous-tibial-nerve-stimulation-by-cigna-300040102.html

SOURCE Uroplasty, Inc.

Copyright 2015 PR Newswire